A study in the Journal of Gastroenterology and Hepatology found that fexuprazan has noninferior efficacy to esomeprazole in patients with erosive esophagitis (EE). The study compared the healing rates of EE between the two medications over an 8-week period. Both fexuprazan and esomeprazole showed similar rates of EE healing at 8 weeks, with no significant difference in adverse events between the two groups. However, fexuprazan showed a trend toward higher symptom resolution and more symptom-free days in the first 7 days, 4 weeks, and 8 weeks of treatment compared to esomeprazole. The study was funded by Daewoong Pharmaceutical Co, Ltd.
Source link
Fexuprazan Noninferior to Esomeprazole for Treating Erosive Esophagitis
